Find Academic Supervisors

Pedro A Hermida de Viveiros, MD serves as an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Northwestern University's Feinberg School of Medicine. His clinical practice focuses on solid tumor oncology with specialized expertise in sarcomas and precision medicine approaches. His research interests center on clinical development of novel therapeutic strategies for sarcomas and gastrointestinal stromal tumors (GIST), emphasizing biomarker-driven treatments and molecularly targeted therapies. Key areas include IDH1-mutant chondrosarcoma management, neoadjuvant response assessment in sarcomas, and immunotherapy-radiotherapy combinations for metastatic disease. Analysis of his recent publications reveals a consistent focus on translating molecular targets into clinical applications, particularly through phase 1-3 trials of targeted agents like ivosidenib and IDRX-42. His work bridges radiological assessment, pathological response, and precision oncology frameworks for rare solid tumors. Professional engagements include active membership in major oncology societies: American Society of Clinical Oncology (ASCO) Connective Tissue Oncology Society (CTOS) Sociedade Brasileira de Oncologia Clínica (SBOC) European Society for Medical Oncology (ESMO) He currently leads four active clinical trials through the Robert H. Lurie Comprehensive Cancer Center, including the CHONQUER phase 3 study of ivosidenib for IDH1-mutant chondrosarcoma and first-in-human trials of novel agents for advanced solid tumors and GIST. His work integrates translational research with clinical trial design to advance personalized treatment paradigms.

• Oncology
• Sarcoma Research
• Precision Medicine
• +3 more

Andrew T Arndt, MD is a Clinical Assistant Professor in the Department of Surgery specializing in Thoracic Surgery at Northwestern University's Feinberg School of Medicine. Board certified by the American Board of Thoracic Surgery, he maintains clinical practice at Northwestern Medicine Central DuPage Hospital and holds active memberships in the Society of Thoracic Surgeons (2023-present) and American Board of Thoracic Surgery (2022-present). His research concentrates on advancing thoracic surgical oncology through investigations into lung cancer resection outcomes, chest wall tumor management, minimally invasive techniques, and pneumothorax recurrence factors. Current work emphasizes evidence-based risk stratification and surgical innovation to improve patient outcomes in complex thoracic pathologies. Recent publications demonstrate consistent focus on surgical registry analysis (2021), consensus development for thoracoscopic training (2021), systematic reviews of rare chest wall malignancies (2023), and identification of lifestyle-related recurrence risks (2021). This trajectory highlights growing contributions to thoracic surgical guidelines and evidence-based practice standards. Dr. Arndt serves as a consultant for Intuitive Surgical, Inc. (2024 disclosures) while maintaining active clinical and academic roles. No formal advisees or research grants are listed in current profile materials. Within Northwestern's Department of Surgery, he contributes to the Thoracic Surgery division's clinical and research missions, particularly in advancing minimally invasive approaches and multidisciplinary management of complex thoracic conditions through collaborative registry studies and consensus initiatives.

• Thoracic Surgery
• Lung Cancer
• Chest Wall Tumors
• +3 more

Xiaofeng Liu is an Assistant Professor at Yale University School of Medicine in the Departments of Radiology & Biomedical Imaging and Biomedical Informatics & Data Science. He is also an Associate Member at the Broad Institute of MIT and Harvard. Previously, he held faculty positions at Harvard Medical School and research roles at Massachusetts General Hospital and Beth Israel Deaconess Medical Center. PhD in Mechatronics from University of Chinese Academy of Sciences Dual Bachelor's degrees in Automation (Wang-Daheng Elite Class) and Communication from University of Science and Technology of China His research integrates trustworthy AI, medical imaging, and data science to improve diagnosis, prognosis, and treatment monitoring for neurological disorders, cancer, and cardiovascular diseases. Key focus areas include domain adaptation techniques, diffusion models, and interpretable AI systems. Led special issues in IEEE Transactions on Pattern Analysis and Medical Image Analysis Developed novel frameworks like Ordinal UDA and Memory-Consistent Adaptation Scientific accolades include the Trailblazer R21 Award (NIBIB), OpenAI Research Award, and National Artificial Intelligence Research Resource Pilot Award. He serves as Associate Editor for IEEE Transactions on Neural Networks and Learning Systems and actively contributes to MICCAI and NIH review panels. His lab at Yale (XLiu Lab) investigates neural basis of intelligence to inspire AI development, with applications in brain tumor segmentation, cardiac imaging, and cross-modal medical diagnostics.

• Artificial Intelligence
• Deep Learning
• Medical Imaging
• +5 more

Alexander Nikitin is a Professor of Pathology at Cornell University's College of Veterinary Medicine, Department of Biomedical Sciences. His research focuses on molecular mechanisms linking tissue homeostasis to cancer development using autochthonous mouse models. Key Affiliation: Cornell University, Ithaca, NY Research Niche: Cancer-prone stem cell niches in female reproductive tract and prostate Research Interests Dr. Nikitin investigates how aberrations in p53/miR-34/MET and Rb networks drive malignant transformation of adult stem cells. His work includes: Identification of ovarian surface epithelium stem cell niche Technology-oriented cross-disciplinary collaborations Characterization of cancer initiation mechanisms in reproductive tissues Article Trends His publications span 2003–2025, emphasizing: Mouse models for epithelial cancers Role of tumor suppressor genes (p53, Rb) in cancer miR-34 family's tumor suppression functions Stem cell niche mapping in reproductive tract cancers Genetic drivers of high-grade serous carcinomas Translational research applications Lab Members Current lab personnel include: Andrea Flesken-Nikitin (Assistant Research Professor) Christopher Ashe (Research Support Specialist) Technicians and student researchers

• Cancer Biology
• Molecular Pathology
• Stem Cell Research
• +3 more

Prim. Clin. Assoc. Prof. PD Dr. Dietmar Dammerer, MSc PhD is the head of the Clinical Department of Orthopaedics and Traumatology at Krems University Hospital, affiliated with Karl Landsteiner Private University of Health Sciences. He has been in this role since February 2022, leading the merger of orthopedics and traumatology into a unified clinical department. A dual-trained specialist, he is recognized for his expertise in endoprosthetics and tumor orthopedics, and actively promotes interdisciplinary collaboration and team-based medicine. His educational background includes a PhD in Musculoskeletal Sciences (2015), an MSc in Advanced Orthopaedics and Traumatology (2017), and board certification in both orthopedics and traumatology (2017, 2018), culminating in habilitation in 2019. He has received prestigious Traveling Fellowships from the European Hip Society and European Musculo-Skeletal Oncology Society. Dietmar Dammerer’s research focuses on orthopedic oncology, joint reconstruction, biomechanics, and minimally invasive surgery. His work emphasizes the integration of clinical inquiry with research to improve patient outcomes. Recent publications analyze pelvic sarcoma reconstruction, spinal metastases, cartilage repair techniques, and health disparities in sarcoma care. His 15 most recent articles reflect a strong trend in musculoskeletal oncology, surgical biomechanics, and evidence-based orthopedic practice, with frequent use of systematic reviews, retrospective studies, and multicenter collaborations. Topics include implant performance, surgical safety, and global access to specialized care. Scientific awards include: Traveling Fellow Stipendium from the European Hip Society (2018) Traveling Fellow Stipendium from the European Musculo-Skeletal Oncology Society (2020) He is deeply committed to mentoring and team development, emphasizing that medical success is measured by the success of one’s colleagues. He leads a research-active department that hosts international observers, conducts training courses for physicians across Europe, the Middle East, and Africa, and maintains a high rate of peer-reviewed publication. The department collaborates closely with the Departments of Biomechanics and Anatomy and Developmental Biology, reflecting a multidisciplinary research approach.

• Orthopedic Surgery
• Traumatology
• Endoprosthetics
• +7 more

Cristina R. Antonescu, MD is the Director of Soft Tissue and Bone Pathology at Memorial Sloan Kettering Cancer Center , affiliated with the Gerstner Sloan Kettering Graduate School of Biomedical Sciences. Her research focuses on the genomic investigation of pediatric and young adult mesenchymal tumors , particularly Novel gene fusion discovery Translocation-associated sarcoma pathogenesis CRISPR-Cas9 engineered models Molecular characterization of kinase fusions Her publications from 2018-2020 highlight breakthroughs in undifferentiated sarcomas , epithelioid hemangioendothelioma , and lipofibromatosis-like neural tumors , revealing key relationships between genetic drivers and clinical outcomes. Research grants include SPORE in Soft Tissue Sarcoma (2018-2023) and Cycle for Survival funding (2018-2021). Contact: antonesc@mskcc.org | Office: 212-639-5721

• Molecular Pathology
• Cancer Genetics
• Genomic Research
• +3 more

Dr. Richard H. Wiggins serves as Professor of Radiology and Imaging Sciences at the University of Utah School of Medicine, where he also holds the position of Associate Dean of Continuing Medical Education. He maintains adjunct professorships in Otolaryngology, Head and Neck Surgery, and Biomedical Informatics. His educational background includes a BA in Biochemistry from the University of Texas at Austin and an MD from the University of Texas at Houston Health Sciences Center, followed by specialized training at the University of Florida and University of Utah. Dr. Wiggins's research spans neuroradiology, biomedical informatics, and medical education innovation. His work explores advanced imaging techniques for head and neck pathologies, PET-CT applications in oncology, and the development of novel educational platforms like the RadDiscord community. He maintains particular expertise in temporal bone imaging, paragangliomas, and thyroid nodule classification systems. Analysis of his recent publications shows strong emphasis on: (1) optimizing oncologic imaging protocols, especially PET-CT applications across cancer types; (2) advancing head and neck radiology through volumetric analysis and radiomics; and (3) transforming radiology education via gamification and digital communities. His scientific honors include: Distinguished Teaching Award (Otolaryngology, University of Utah) Honored Educator Award (Radiological Society of North America) Inaugural Fellow, Academy of Health Science Educators 25th Fellow of the Society of Imaging Informatics in Medicine Fellow of the American College of Radiology He leads the Utah Head and Neck Imaging Center of Excellence, which includes an educational YouTube channel (@UHNICE). While specific grants aren't detailed, his extensive lecture record (600+ presentations) and leadership roles in professional societies like SIIM (Program Chair 2014-2020), ASHNR (Past President), and WNRS (Past President) demonstrate significant academic influence.

• Neuroradiology
• Biomedical Informatics
• Head and Neck Imaging
• +3 more

G. Petur Nielsen, MD is a Professor of Pathology at Harvard Medical School and serves as Subspecialty Head, Bone and Soft Tissue Pathology at Massachusetts General Hospital . With a clinical focus on bone and soft tissue tumors, his expertise spans diagnostic pathology, molecular genetics of neoplasms, and ancillary testing applications. Research interests center on Pathology and biology of bone/soft tissue tumors Molecular genetics of bone and soft tissue neoplasms Chordoma and sarcoma research Epithelioid vascular tumor differentiation Mesenchymal tumors of the female genital tract His work includes landmark studies on tumor misdiagnosis rates, immunohistochemical profiling, and genomic analysis of chordomas. Scientific contributions appear in leading journals like Nature and American Journal of Surgical Pathology , with major emphasis on Molecular tumor classification Mutational signature analysis Translational oncology Diagnostic accuracy improvement Genomic instability mechanisms

• Bone and Soft Tissue Pathology
• Molecular Genetics of Bone Tumors
• Chordoma Research
• +5 more

Dr. Megan Anderson is Associate Professor of Orthopedic Surgery at Harvard Medical School and Director of the Orthopedic Oncology Program at Boston Children's Hospital. She completed her MD at University of Florida College of Medicine (1998), residency at Cleveland Clinic Foundation, and fellowship at Harvard-affiliated hospitals (2004). Her clinical practice focuses on bone tumors and sarcomas in pediatric and young adult populations. Research examines surgical outcomes in bone cancer treatment, particularly limb-salvage techniques and reconstruction complications. Recent publications analyze cost-effectiveness of preventive interventions in metastatic bone disease. Leads multidisciplinary collaborations through the Bone and Soft Tissue Tumors Program. Active in Musculoskeletal Tumor Society and Children's Oncology Group.

• Orthopedic Oncology
• Bone Cancer Surgery
• Sarcoma Treatment
• +2 more

Elliot A. Asare, MD, MS, CMQ, FACS serves as Assistant Professor in the Section of Surgical Oncology within the Division of General Surgery at the University of Utah. He specializes in cutaneous malignancies and sarcomas of the retroperitoneum and soft tissues, practicing clinically at both Huntsman Cancer Institute and Intermountain Healthcare Center in Murray. His educational trajectory includes: Phi Beta Kappa graduate with B.S. in Biology and Chemistry (double major) from Randolph-Macon College M.D. from Howard University College of Medicine (Alpha Omega Alpha inductee) General Surgery residency at Medical College of Wisconsin Affiliated Hospitals M.S. in Health Services and Outcomes Research from Northwestern University Complex General Surgical Oncology fellowship at University of Texas MD Anderson Cancer Center Dr. Asare's research program centers on cancer staging methodology, data quality enhancement, prognostication frameworks, and outcomes research with emphasis on health disparities. His work integrates large-scale database analyses (SEER, National Cancer Data Base) to refine AJCC staging systems while addressing inequities in melanoma and sarcoma care across elderly, minority, and rural populations. Recent investigations explore sentinel lymph node biopsy efficacy in aging patients and viral infection impacts on melanoma mortality. His 2023-2025 publications reveal three dominant themes: (1) AJCC Version 9 implementation across multiple cancer types (anal, appendiceal, neuroendocrine), (2) persistent disparities in skin cancer outcomes linked to demographic and geographic factors, and (3) telehealth applications for expanding surgical oncology access. These studies consistently leverage national datasets to validate staging systems while identifying structural barriers to equitable care. Professional recognition includes: Phi Beta Kappa honor society membership Alpha Omega Alpha Medical Honor Society induction Fellowship in the American College of Surgeons (FACS) Dr. Asare actively contributes to surgical oncology education through The SCORE Portal as item writer for soft tissue neoplasm assessments and via publications on medical education frameworks. His institutional affiliations with Huntsman Cancer Institute and Intermountain Healthcare provide platforms for multidisciplinary sarcoma and melanoma management, where he integrates evidence-based staging protocols with patient-centered surgical approaches as evidenced by consistently high patient satisfaction scores (4.9/5 from 166 reviews).

• Cancer Staging
• Outcomes Research
• Surgical Oncology
• +5 more

Lauren Baker Banks is a Clinical Assistant Professor in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). She is affiliated with the Hematology-Oncology Fellows and Graduate Medical Education (GME) programs, and her research focuses on sarcoma biology and immune checkpoint blockade (ICB) therapies. Affiliations: Hematology-Oncology Fellows, Graduate Medical Education (GME), Department of Medicine, Solid Tumor Oncology Division, Division of Hematologic Malignancies Co-authors: Sandra D'Angelo, Ciara Kelly, Evan Rosenbaum, Jason Chan, Mark Dickson, Mary Keohan Her work spans clinical trials in leiomyosarcoma, dedifferentiated liposarcoma, and other sarcomas, with a focus on combination therapies involving PARP inhibitors, PD-1 inhibitors, and STING agonists. Recent studies analyze biomarkers like T cell phenotype and tumor microenvironment subtypes to predict ICB outcomes. Lauren's publications include contributions to Journal for ImmunoTherapy of Cancer , Annals of Oncology , and Journal of Clinical Oncology , with a strong emphasis on translational research linking immunology to sarcoma treatment. She has collaborated with key researchers in oncology and immunotherapy, including Evan Rosenbaum and Ciara Kelly. Her research activities align with histology-specific clinical trials and multidisciplinary approaches for extremity soft tissue sarcomas, highlighting the integration of targeted therapy, immunotherapy, and genomic profiling in advancing sarcoma care.

• Medical Oncology
• Cancer Immunotherapy
• Sarcoma Research
• +3 more

Christine Mona is an Adjunct Assistant Professor in the Department of Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA). Her research focuses on experimental and translational oncology, particularly the role of Fibroblast Activation Protein (FAP) and Prostate-Specific Membrane Antigen (PSMA) in tumor biology and radioligand therapy for prostate, sarcoma, and pancreatic cancers. PhD in Pharmacology , Université de Sherbrooke (2016) MOOC in Project Management, École Centrale de Lille (2015) MSc in Biomolecular Chemistry , Université de Montpellier (2010) BSc in Biomolecular Chemistry , Université de Montpellier (2008) Christine's research explores FAP-positive cells in cancer tumorigenesis and therapeutic resistance. She evaluates FAP-targeted Radioligand Therapy (RNT) as a novel approach, using animal models to investigate resistance mechanisms and design combination therapies for clinical translation in nuclear medicine. Her recent publications (2023–2025) demonstrate a focus on targeted alpha therapy , radioligand toxicity profiles , and combination treatments for prostate cancer, sarcoma, and glioblastoma. Key methodologies include PET imaging , immunohistochemistry , and in vivo models to validate therapeutic strategies.

• Translational Oncology
• Experimental Oncology
• Cancer Biology
• +3 more

Gregory Skladzien, MD is an Assistant Professor at Rosalind Franklin University of Medicine and Science with dual appointments in the College of Health Professions (Physician Assistant Department) and Chicago Medical School (Department of Foundational Sciences and Humanities, Cell Biology and Anatomy), holding these positions since 2004 and 2003 respectively. Dr. Skladzien's educational background includes: BA summa cum laude from North Central College (1974) MD cum laude from Loyola University Stritch School of Medicine (1976) Residency in General Surgery at Loyola University Affiliated Hospitals (1976-1981) His research focuses on General Surgery with specialization in abdominal wall procedures, hernia management, and surgical oncology. His work bridges clinical practice with foundational sciences through dual departmental appointments in anatomy and cell biology, emphasizing case-based surgical education and age-related surgical challenges. His publication history from 1982-2006 features clinically significant case reports on rare surgical conditions including typhoid-related appendicitis and cutaneous sarcomas, alongside encyclopedia contributions on hernias in aging populations. These works demonstrate consistent expertise in complex general surgery with emphasis on public health implications. Professional recognition includes: Fellow, American College of Surgeons (1983-2000) No graduate student advising or research grants are documented in available records. Clinical practice history shows transition from active surgical service to emeritus status at Resurrection Medical Center since 2003.

• General Surgery
• Anatomy
• Cell Biology
• +3 more

Professor Torsten Nielsen is a clinician-scientist at the University of British Columbia 's Department of Pathology & Laboratory Medicine (Faculty of Medicine), based at Vancouver General Hospital and BC Cancer . He directs UBC's MD/PhD Program , contributes to cancer clinical trials with the Canadian Cancer Trials Group , and chairs the international Connective Tissue Oncology Society 's Research Committee. Key affiliations: UBC, Vancouver General Hospital, BC Cancer, Molecular and Advanced Pathology Core Academic focus: Translational research in sarcomas and breast cancer His research prioritizes translating genomic discoveries into clinical diagnostics and treatments, particularly for synovial sarcoma , breast cancer subtypes , and tenosynovial giant cell tumors . He develops FDA-cleared molecular assays like the PAM50 (Prosigna) test and leads pan-Canadian precision oncology initiatives . Collaborative efforts include work with Stanford, Leiden, and DKFZ Heidelberg. Recent publications highlight advancements in epigenetic therapies , immune biomarker validation , and synovial sarcoma pathogenesis . His lab's work on CSF1/CSF1R signaling inspired new treatment strategies for joint-destructive tumors. Scientific Awards: Fellow, Canadian Academy of Health Sciences Fellow, Royal Society of Canada As director of UBC's MD/PhD Program, he trains future clinician-scientists. His lab team includes experts in epigenomics , proteomics , and mouse modeling . Current projects focus on precision oncology for sarcomas and Ki67 standardization in breast cancer.

• Sarcoma
• Breast Cancer
• Molecular Diagnostics
• +7 more

Gregory T. MacLennan, MD is a Professor in the Department of Pathology and Department of Urology at the School of Medicine, Case Western Reserve University (CWRU), and a Physician at University Hospitals Cleveland Medical Center (UHCMC). He earned his MD from the University of Manitoba in 1971 and completed surgical and urology training in Canada and a urodynamics fellowship in the UK. After clinical practice in urology, he transitioned to anatomic pathology, completing further training at Mayo Clinic. Education: MD, University of Manitoba (1971) Fellowship in Urodynamics, St. Peter’s Hospitals, London (1977–1978) Training in Anatomic Pathology & Cytopathology, Manitoba Affiliated Teaching Hospitals (1989–1994) Fellowship in Surgical/Urologic Pathology, Mayo Clinic (1994–1995) Research Interests: Dr. MacLennan specializes in genitourinary pathology, focusing on diagnostic surgical and cytopathology. His work integrates clinical and basic science collaborations, addressing urogenital and reproductive system pathologies. Key areas include tumors like liposarcoma, renal pseudotumors, and urachal adenocarcinoma, emphasizing multidisciplinary approaches with urologists, oncologists, and radiologists. Key Roles: Director of Human Tissue Procurement Facility (17 years) Director of Surgical Pathology (8 years) Division Chief of Anatomic Pathology (7 years) Editorial Board Member, Journal of Urology (7 years) Awards: 2015: Inducted into CWRU Urology Department Hall of Fame Specialist Certification: Royal College of Physicians and Surgeons of Canada Board Certification: American Boards of Urology and Pathology Labs & Collaborations: Collaborates with clinical and basic science teams across UHCMC and CWRU, contributing to advancements in diagnostic and molecular pathology.

• Genitourinary Pathology
• Surgical Pathology
• Cytopathology
• +3 more